• In recent days IMAX Corporation and Asian Cinemas agreed to open three new IMAX with Laser locations in India under the AMB Cinemas brand, marking IMAX’s return to Hyderabad and extending its premium footprint in a market that delivered a record US$25.6 million box office for IMAX India in 2025.
• Alongside this expansion, IMAX’s move to quickly slot Amazon’s “Masters of the Universe” into IMAX screens after pulling “The Mandalorian and Grogu” highlights how actively the company manages its premium screen inventory to prioritize content it expects to resonate better with audiences.
• Next, we’ll examine how IMAX’s renewed India expansion through Asian Cinemas may influence the company’s wider investment narrative and growth thesis.

We've uncovered the 10 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

IMAX Investment Narrative Recap

To own IMAX, you need to believe premium, event-style cinema can keep earning attractive returns despite competition from at-home entertainment. Near term, the key catalyst is how effectively IMAX monetizes its premium screens with audience-friendly titles, while the main risk is continued reliance on a volatile blockbuster slate. The recent swap of “The Mandalorian and Grogu” for “Masters of the Universe” illustrates active content management, but it does not fundamentally change those risks or drivers.

The Asian Cinemas deal in India looks most relevant here. It ties IMAX’s content choices to a market that delivered a record US$25.6 million box office in 2025 and is becoming central to its local-language strategy. As IMAX adds Hyderabad back to its network with IMAX with Laser systems, that growing international footprint could support future box office and installation-related revenue, but it also raises the stakes if tentpole content underperforms.

Yet behind IMAX’s premium screens, investors should be aware that...

IMAX's narrative projects $513.8 million revenue and $134.2 million earnings by 2029.

Uncover how IMAX's forecasts yield a $46.82 fair value, a 20% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming IMAX could lift revenue to about US$487.3 million and earnings to roughly US$76.7 million by 2028, so if you think live sports and alternative content on IMAX screens really take off after deals like the Asian Cinemas expansion, your view might sit closer to that bullish camp than the more cautious consensus.

Explore 3 other fair value estimates on IMAX - why the stock might be worth as much as 25% more than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your IMAX research is our analysis highlighting 4 key rewards and 2 important warning signs that could impact your investment decision.
• Our free IMAX research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate IMAX's overall financial health at a glance.

Want Some Alternatives?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• AI is about to change healthcare. These 39 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 13 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.